Alzheimer's Drug Discovery Foundation Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer's Disease
Alzheimer's Drug Discovery Foundation Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer's Disease
09/23/20, 2:17 PM
Location
new yorkThe Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded more than $2.2 million to C2N Diagnostics to accelerate clinical validation and accreditation of its beta-amyloid blood test for early detection of Alzheimer's disease pathology. The ADDF has been a long-time supporter of research into Alzheimer's biomarkers, including this amyloid blood test, providing $2.8 million in funding to C2N over the last decade.
Company Info
Location
new york, new york, united states
Additional Info
The Alzheimer's Drug Discovery Foundation is the only public charity solely focused on funding the development of drugs for Alzheimer's disease, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $150 million to fund over 626 Alzheimer's drug discovery programs and clinical trials in 19 countries. To learn more, please visit: https://www.alzdiscovery.org/.